Revvity Inc.
$ 116.03
1.19%
10 Aug - close price
- Market Cap 12,791,444,000 USD
- Current Price $ 116.03
- High / Low $ 116.74 / 112.68
- Stock P/E 55.12
- Book Value 64.76
- EPS 2.08
- Next Earning Report -
- Dividend Per Share $0.14
- Dividend Yield 0.12 %
- Next Dividend Date 2026-11-13
- ROA 0.02 %
- ROE 0.03 %
- 52 Week High 118.13
- 52 Week Low 81.14
About
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets globally. The company is headquartered in Waltham, Massachusetts.
Analyst Target Price
$121.07
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-27 | 2026-05-05 | 2026-02-02 | 2025-10-27 | 2025-07-28 | 2025-04-28 | 2025-01-31 | 2024-11-04 | 2024-07-29 | 2024-04-29 | 2024-02-01 | 2023-10-30 |
| Reported EPS | 1.41 | 1.06 | 1.7 | 1.18 | 1.18 | 1.01 | 1.42 | 1.28 | 1.22 | 0.98 | 1.25 | 1.18 |
| Estimated EPS | 1.23 | 1.01 | 1.58 | 1.14 | 1.14 | 0.95 | 1.38 | 1.13 | 1.12 | 0.94 | 1.16 | 1.19 |
| Surprise | 0.18 | 0.05 | 0.12 | 0.04 | 0.04 | 0.06 | 0.04 | 0.15 | 0.1 | 0.04 | 0.09 | -0.01 |
| Surprise Percentage | 14.6341% | 4.9505% | 7.5949% | 3.5088% | 3.5088% | 6.3158% | 2.8986% | 13.2743% | 8.9286% | 4.2553% | 7.7586% | -0.8403% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Aug 2026 | May 2026 | Feb 2026 | Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 | May 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-08-07 | 2026-05-08 | 2026-02-06 | 2025-11-07 | 2025-08-08 | 2025-05-09 | 2025-02-07 | 2024-11-08 | 2024-08-09 | 2024-05-10 |
| Amount | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 |
Next Dividend Records
| Dividend per share (year): | $0.14 |
| Dividend Yield | 0.12% |
| Next Dividend Date | 2026-11-13 |
| Ex-Dividend Date | 2026-10-23 |
Recent News: RVTY
2026-08-10 17:51:58
Revvity has introduced the SuperFlex prenatal screening system, a compact immunoassay instrument designed for small to mid-sized laboratories and clinics to offer preeclampsia testing and biochemical screening. This CE-IVDR certified system aims to lower financial and operational barriers to in-house prenatal screening, providing access to potentially life-saving testing for more women. The SuperFlex system is initially available in markets accepting CE-marked instruments, with expansion into the Asia-Pacific region planned for late 2026.
2026-08-10 14:39:24
Morningstar analyst Julie Utterback published a report on Revvity, Inc. (RVTY), a global life sciences and diagnostics company. The report, titled "Revvity Earnings: Strong but Dressed-Up Quarter Boosts 2026 Outlook," was released on August 4, 2026. Revvity operates in life sciences and signals software segments, and the report is exclusively available through Yahoo Finance Silver.
2026-08-10 12:00:11
Revvity has launched the SuperFlex prenatal screening system, a compact and affordable immunoassay instrument designed to make preeclampsia testing more accessible to small to mid-sized labs and clinics. This system aims to overcome financial and operational barriers that previously limited such testing to larger, centralized laboratories, thereby expanding access to potentially life-saving screening for pregnant women. The platform is CE-IVDR certified and offers operational simplicity, flexible throughput, and a test menu for both first- and second-trimester biochemical prenatal screening.
2026-08-09 03:38:53
Revvity (RVTY) reported strong second-quarter results, exceeding expectations and raising its full-year outlook due to robust diagnostics performance and increasing demand from pharmaceutical and biotech sectors, particularly in AI-enabled drug discovery. The company saw pro forma organic revenue growth of 3% and adjusted earnings per share of $1.41. Revvity’s CFO highlighted significant contributions from the Diagnostics segment and improving order activity in Life Sciences, especially for AI-driven drug discovery tools.
2026-08-08 09:08:02
This article provides a comprehensive overview of IDEXX Laboratories, Inc. (IDXX) stock, including its current price, key financial statistics, historical performance, and analyst ratings. It details the company's operations in animal diagnostics, water quality, and veterinary software, and compares its performance to benchmarks like the S&P 500 and similar companies. The content is current as of August 7, 2026, with an analyst rating update on August 5, 2026.
2026-08-07 23:38:57
Revvity, Inc. (RVTY) reported strong Q2 2026 results with increased revenue guidance for the full year, driven by improving pharma/biotech demand and robust Diagnostics performance. The company is strategically exiting its China immunodiagnostics business to focus on higher-margin areas, aiming for a narrative built around Diagnostics and software growth. While analysts are optimistic, regulatory risks in healthcare and China remain a key consideration for investors.
